SynuCa Therapeutics are pioneering a novel approach to treating Parkinson’s disease and related neurodegenerative disorders. Their lead compound, SYN4569, is a first-in-class small molecule that targets the SERCA calcium transporter, aiming to restore neuronal calcium balance disrupted by pathological α-synuclein aggregates, potentially modifying disease progression.